<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727282</url>
  </required_header>
  <id_info>
    <org_study_id>VTI-TAPSE</org_study_id>
    <nct_id>NCT03727282</nct_id>
  </id_info>
  <brief_title>Left Ventricular Volume Index in the Adjustment of Initial Dose of Dobutamine in Heart Failure and Cardiogenic Shock</brief_title>
  <official_title>Use of Transtoracic Ecocargiogram With Calculation of Left Ventricular Volume Index in the Initial Adjustment of Initial Dose of Dobutamine in Patients With Heart Failure and Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have suggested that the use of left ventricular ejection volume index&#xD;
      calculation may aid in the hemodynamic management of critically ill patients. However, a&#xD;
      prospective and randomized comparison in patients with heart failure for inotropic dose&#xD;
      adjustment has not been described. The objective of this study was to evaluate the efficacy&#xD;
      and safety of ejection volume index versus liberal strategy in adjusting dobutamine dose in&#xD;
      patients with heart failure and low cardiac output. Methodology: A unicentric, randomized and&#xD;
      prospective study will be performed in a comparative manner. Hospital data (test results,&#xD;
      medical outcomes, dobutamine dose, complications) of patients will be analyzed for safety and&#xD;
      effectiveness. Expected results: The use of ejection volume index is not inferior to the&#xD;
      liberal strategy in the initial adjustment of the dose of dobutamine in patients with heart&#xD;
      failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">January 2, 2019</start_date>
  <completion_date type="Anticipated">January 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>base excess levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bicarbonate levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>systolic and diastolic blood pressure</measure>
    <time_frame>24 hours</time_frame>
    <description>physical evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiac output</measure>
    <time_frame>24 hours</time_frame>
    <description>echocardiography echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>systolic volume</measure>
    <time_frame>24 hours</time_frame>
    <description>echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urinary output</measure>
    <time_frame>24 hours</time_frame>
    <description>urine analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>arterial lactate levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>central venous oxygen saturation levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BNP levels</measure>
    <time_frame>24 hours</time_frame>
    <description>plasma analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>troponin levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate</measure>
    <time_frame>24 hours</time_frame>
    <description>physical evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>creatinine levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urea levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of sustained ventricular arrhythmia</measure>
    <time_frame>24 hours</time_frame>
    <description>electrocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for orotracheal intubation</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for vasopressor or other inotropic association</measure>
    <time_frame>24 hours</time_frame>
    <description>hipotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for mechanical circulatory assistance</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lowering of consciousness level</measure>
    <time_frame>24 hours</time_frame>
    <description>glasgow &lt; 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiorespiratory arrest</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worsening of renal function</measure>
    <time_frame>24 hours</time_frame>
    <description>increase 0.5 mg / dl in relation to admission creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failure of dobutamine weaning up</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization time</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Liberal strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the attending physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ejection volume index</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the ejection volume index</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjust dobutamine according to the ejection volume index</intervention_name>
    <description>adjust dobutamine dose</description>
    <arm_group_label>ejection volume index</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjust dobutamine according to the attending physician</intervention_name>
    <description>adjust dobutamine dose</description>
    <arm_group_label>Liberal strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  LVEF ≤ 40% documented on echocardiography&#xD;
&#xD;
          -  BNP&gt; 500 pg / mL&#xD;
&#xD;
          -  Need for initiation of dobutamine and signs or symptoms of low cardiac output at&#xD;
             admission defined by the presence of 2 or more of the following:&#xD;
&#xD;
               -  SBP ≤ 95 mmHg&#xD;
&#xD;
               -  FC&gt; 100 bpm&#xD;
&#xD;
               -  Peripheral vasoconstriction,&#xD;
&#xD;
               -  Cold extremities,&#xD;
&#xD;
               -  Reference of decrease of urine output,&#xD;
&#xD;
               -  Nausea, vomiting and food intolerance,&#xD;
&#xD;
               -  Presence of organic dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  COPD&#xD;
&#xD;
          -  Hepatical cirrhosis&#xD;
&#xD;
          -  Atrioventricular block of 2nd or 3rd degree. and. SBP &lt;80 mmHg or need for&#xD;
             vasopressor.&#xD;
&#xD;
          -  Use of definitive pacemaker.&#xD;
&#xD;
          -  Body mass index greater than 40 kg / m2.&#xD;
&#xD;
          -  Use of oral anticoagulant.&#xD;
&#xD;
          -  Acute coronary syndrome.&#xD;
&#xD;
          -  Indication of use of another inotropic other than dobutamine.&#xD;
&#xD;
          -  Orotracheal intubation.&#xD;
&#xD;
          -  Presence of significant pericardial effusion.&#xD;
&#xD;
          -  Obstruction of left ventricular outflow tract.&#xD;
&#xD;
          -  Serum creatinine&gt; 5.0 mg / dL or hemodialysis.&#xD;
&#xD;
          -  Presence of 2 or more clinical / laboratory / radiological criteria of infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mucio Tavares, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidade Clínica de Emergência</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Soeiro, MD</last_name>
    <phone>1126615299</phone>
    <email>alexandre.soeiro@bol.com.br</email>
  </overall_contact>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

